

Listing of the claims

1.-9. (Canceled)

10. (Withdrawn) A polynucleotide comprising polynucleotides encoding a binding molecule according to claim 1.

11. (Withdrawn, Currently amended) A polynucleotide comprising either polynucleotide sequences as shown in SEQ ID NO: 14, SEQ ID NO: 15 and SEQ ID NO: 16; or polynucleotide sequences as shown in SEQ ID NO: 17, SEQ ID NO: 18 and SEQ ID NO: 19.

12. (Withdrawn) An expression vector comprising polynucleotides according to claim 10.

13. (Withdrawn) An expression system comprising a polynucleotide according to claim 10, wherein said expression system or part thereof is capable of producing a polypeptide of claim 1, when said expression system or part thereof is present in a compatible host cell.

14. (Withdrawn) An isolated host cell which comprises an expression system according to claim 13.

15. (Withdrawn, Currently amended) The use of a binding molecule according to any one of claims 19, 20, 21, 22, 23 and 24 [[claim 1]] as a pharmaceutical.

16. (Withdrawn, Currently amended) The use of a binding molecule according to any one of claims 19, 20, 21, 22, 23 and 24 [[claim 1]] in the treatment of nerve repair.

17. (Currently amended) A pharmaceutical composition comprising a binding molecule according to any one of claims 19, 20, 21, 22, 23 and 24 [[claim 1]] in association with at least one pharmaceutically acceptable carrier or diluent.

18. (Withdrawn, Currently amended) A method of treatment of diseases associated with nerve repair comprising administering to a subject in need of such treatment an effective amount of a binding molecule according to any one of claims 19, 20, 21, 22, 23 and 24 [[claim 1]] .
19. (New) An isolated human Nogo_A623-640 binding molecule which comprises a heavy chain variable domain or fragment thereof comprising in sequence SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO.10.
20. (New) An isolated human Nogo_A623-640 binding molecule which comprises a light chain variable domain or fragment thereof comprising in sequence SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO.13.
21. (New) An isolated human Nogo_A623-640 binding molecule which comprises a heavy chain variable domain or fragment thereof comprising in sequence SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO.10; and a light chain variable domain or fragment thereof comprising in sequence SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO.13.
22. (New) An isolated human Nogo_A623-640 binding molecule comprising at least one antigen binding site, said antigen binding site comprising in sequence CDR1, CDR2 and CDR3, wherein
- (a) CDR1 is at least 90% homologous to SEQ ID NO:8;
 - (b) CDR2 is at least 90% homologous to SEQ ID NO:9; and
 - (c) CDR3 is at least 90% homologous to SEQ ID NO:10.
23. (New) An isolated human Nogo_A623-640 binding molecule comprising at least one antigen binding site, said antigen binding site comprising in sequence CDR1', CDR2' and CDR3', wherein
- (a) CDR1' is at least 90% homologous to SEQ ID NO:11;
 - (b) CDR2' is at least 90% homologous to SEQ ID NO:12; and
 - (c) CDR3' is at least 90% homologous to SEQ ID NO:13.

24. (New) An isolated human Nogo_A623-640 binding molecule which comprises
- (1) a first antigen binding site comprising in sequence CDR1, CDR2 and CDR3, wherein
 - (a) CDR1 is at least 90% homologous to SEQ ID NO:8;
 - (b) CDR1 is at least 90% homologous to SEQ ID NO:9;
 - (c) CDR1 is at least 90% homologous to SEQ ID NO:10; and
 - (2) a second antigen binding site comprising in sequence CDR1', CDR2' and CDR3', wherein
 - (a) CDR1' is at least 90% homologous to SEQ ID NO:11;
 - (b) CDR2' is at least 90% homologous to SEQ ID NO:12; and
 - (c) CDR3' is at least 90% homologous to SEQ ID NO:13.